• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组白细胞介素2刺激过继转移的淋巴因子激活的杀伤细胞(LAK细胞)在体内增殖。

Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

作者信息

Ettinghausen S E, Lipford E H, Mulé J J, Rosenberg S A

出版信息

J Immunol. 1985 Nov;135(5):3623-35.

PMID:3900213
Abstract

We previously reported that the adoptive transfer of lymphokine-activated killer (LAK) cells plus repetitive injections of recombinant interleukin 2 (IL 2) produced a marked reduction in established pulmonary metastases from a variety of murine sarcomas. The requirement for the exogenous administration of IL 2 prompted a subsequent examination of the role of IL 2 in the in vivo function of transferred LAK cells. The in vivo proliferation and migration patterns of lymphoid cells in C57BL/6 mice were examined after i.v. transfer of LAK cells alone, i.p. injection of IL 2 alone, or the combination of LAK cells and IL 2. A model for in vivo labeling of the DNA of dividing cells was used in which mice were injected with 5-[125I]-iodo-2'-deoxyuridine (125IUdR) and, 20 hr later, their tissues were removed and were counted in a gamma analyzer. A proliferation index (PI) was calculated by dividing the mean cpm of organs of experimentally treated mice by the mean cpm of organs of control mice. In animals given LAK cells alone, the lungs and liver demonstrated little if any uptake of 125IUdR above saline-treated controls (PI = 2.5 and 0.8, respectively, on day 5), whereas the same organs of mice receiving 6000 U of IL 2 alone displayed higher radiolabel incorporation (PI = 7.1 and 5.9, respectively). When mice were given LAK cells plus 6000 U of IL 2, their tissues showed an additional increase in 125IUdR uptake. In the spleen, kidneys, and mesenteric lymph nodes, IL 2 treatment alone (6000 U) produced elevated PI values that were not, however, additionally increased if LAK cells were also administered. To separate the stimulatory effects of IL 2 on host lymphocyte proliferation from similar IL 2 effects on injected LAK cells, these studies were repeated in mice immunosuppressed by 500 rad total body irradiation. Pre-irradiation of the host sufficiently reduced endogenous lymphoid expansion stimulated by IL 2 so as to allow the demonstration that IL 2 also induced the proliferation of the transferred LAK cells. A variety of studies confirmed that the injected LAK cells were actively proliferating in tissues in vivo under the influence of IL 2. Substitution of "normal" LAK cells with fresh and cultured (without IL 2) splenocytes, or irradiated LAK cells did not result in increased 125IUdR uptake in tissues. Histologic studies corroborated the findings of the 125IUdR incorporation assays and revealed extensive lymphoid proliferation in irradiated mice receiving LAK cells plus IL 2.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

我们之前报道过,过继转移淋巴因子激活的杀伤细胞(LAK细胞)并重复注射重组白细胞介素2(IL-2),可使多种小鼠肉瘤已形成的肺转移灶显著减少。由于需要外源性给予IL-2,促使我们随后研究IL-2在过继转移的LAK细胞体内功能中的作用。分别静脉注射单独的LAK细胞、腹腔注射单独的IL-2,或同时给予LAK细胞和IL-2后,检测C57BL/6小鼠体内淋巴细胞的增殖和迁移模式。采用一种体内标记分裂细胞DNA的模型,给小鼠注射5-[125I]-碘-2'-脱氧尿苷(125IUdR),20小时后取出组织,用γ分析仪进行计数。通过将经实验处理小鼠器官的平均每分钟计数(cpm)除以对照小鼠器官的平均cpm来计算增殖指数(PI)。单独给予LAK细胞的动物,其肺和肝脏对125IUdR的摄取量与生理盐水处理的对照相比几乎没有增加(第5天PI分别为2.5和0.8),而单独接受6000 U IL-2的小鼠的相同器官显示出更高的放射性标记掺入(PI分别为7.1和5.9)。当给小鼠同时给予LAK细胞和6000 U IL-2时,它们的组织对125IUdR的摄取量进一步增加。在脾脏、肾脏和肠系膜淋巴结中,单独给予IL-2(6000 U)可使PI值升高,但如果同时给予LAK细胞则不会进一步升高。为了区分IL-2对宿主淋巴细胞增殖的刺激作用与对注射的LAK细胞的类似作用,在接受500拉德全身照射免疫抑制的小鼠中重复了这些研究。对宿主进行照射前预处理可充分减少IL-2刺激的内源性淋巴细胞扩增,从而能够证明IL-2也可诱导过继转移的LAK细胞增殖。各种研究证实,在IL-2的影响下,注射的LAK细胞在体内组织中积极增殖。用新鲜的和培养的(无IL-2)脾细胞或经照射的LAK细胞替代“正常”LAK细胞,并未导致组织中125IUdR摄取增加。组织学研究证实了125IUdR掺入试验的结果,并显示在接受LAK细胞加IL-2的照射小鼠中有广泛的淋巴细胞增殖。(摘要截短于400字)

相似文献

1
Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.重组白细胞介素2刺激过继转移的淋巴因子激活的杀伤细胞(LAK细胞)在体内增殖。
J Immunol. 1985 Nov;135(5):3623-35.
2
Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.重组白细胞介素2的全身给药可刺激体内组织中的淋巴细胞增殖。
J Immunol. 1985 Aug;135(2):1488-97.
3
In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.在小鼠体内给予α干扰素和白细胞介素2可诱导淋巴样细胞在小鼠器官中增殖。
Cancer Res. 1990 Sep 1;50(17):5543-50.
4
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.使用淋巴因子激活的杀伤细胞对小鼠肉瘤进行免疫治疗:重组白细胞介素-2给药方案和途径的优化
Cancer Res. 1986 Jun;46(6):2784-92.
5
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.淋巴因子激活的杀伤细胞和重组白细胞介素2在体内的抗肿瘤疗效:已形成转移灶的减少与淋巴因子激活的杀伤细胞的细胞溶解活性之间的直接相关性。
J Immunol. 1986 May 15;136(10):3899-909.
6
Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.对小鼠进行重组白细胞介素-6的全身给药可在体内诱导淋巴细胞增殖。
Lymphokine Cytokine Res. 1992 Jun;11(3):133-9.
7
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.用淋巴因子激活的杀伤细胞和重组白细胞介素-2对小鼠实验性肝转移进行成功的免疫治疗。
Cancer Res. 1985 Aug;45(8):3735-41.
8
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.淋巴因子激活的杀伤细胞和重组白细胞介素2在体内的抗肿瘤疗效。
J Immunol. 1985 Jul;135(1):646-52.
9
Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.用淋巴因子激活的杀伤细胞(LAK)和重组白细胞介素2(RIL-2)对小鼠肝转移瘤进行过继性免疫治疗,可介导免疫原性和非免疫原性肉瘤以及一种腺癌的消退。
J Immunol. 1985 Dec;135(6):4273-80.
10
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.淋巴因子激活的杀伤细胞和重组白细胞介素-2在体内的抗肿瘤疗效:接受免疫治疗小鼠的生存获益及肿瘤逃逸机制
Cancer Res. 1986 Feb;46(2):676-83.

引用本文的文献

1
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.肿瘤浸润淋巴细胞(TILs)细胞疗法:训练和驯化 T 细胞以对抗癌症。
Front Immunol. 2021 Jun 1;12:690499. doi: 10.3389/fimmu.2021.690499. eCollection 2021.
2
Redirecting the Immune Microenvironment in Acute Myeloid Leukemia.重定向急性髓系白血病中的免疫微环境
Cancers (Basel). 2021 Mar 20;13(6):1423. doi: 10.3390/cancers13061423.
3
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.白血病免疫逃逸的机制及其在单倍体造血细胞移植后复发中的作用。
Front Immunol. 2020 Feb 25;11:147. doi: 10.3389/fimmu.2020.00147. eCollection 2020.
4
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?白细胞介素-2在肾细胞癌中的应用:已是明日黄花还是仍具可行性?
J Kidney Cancer VHL. 2014 Nov 23;1(7):74-83. doi: 10.15586/jkcvhl.2014.18. eCollection 2014.
5
Passive immunotherapeutic strategies for the treatment of malignant gliomas.用于治疗恶性脑胶质瘤的被动免疫治疗策略。
Neurosurg Clin N Am. 2012 Jul;23(3):481-95. doi: 10.1016/j.nec.2012.04.008.
6
Long-term culture of human LAK cells.人淋巴因子激活的杀伤细胞的长期培养
Cytotechnology. 1991 Feb;5(Suppl 1):139-40. doi: 10.1007/BF00736833.
7
Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.活化淋巴细胞在小鼠体内向RENCA肿瘤微循环的转运。
Br J Cancer. 1997;76(12):1572-8. doi: 10.1038/bjc.1997.599.
8
Leucocyte interactions with the mouse cremaster muscle microcirculation in vivo in response to tumour-conditioned medium.白细胞在体内与小鼠提睾肌微循环的相互作用,以响应肿瘤条件培养基。
Br J Cancer. 1997;75(7):993-9. doi: 10.1038/bjc.1997.171.
9
Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.通过灭活肿瘤细胞与重组白细胞介素-2联合治疗在体内产生肿瘤特异性细胞毒性T淋巴细胞。
Cancer Immunol Immunother. 1994 May;38(5):332-8. doi: 10.1007/BF01525512.
10
Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.富含溶酶体的细胞含有淋巴因子激活的杀伤细胞群体的裂解活性。
Cancer Immunol Immunother. 1987;24(3):247-52. doi: 10.1007/BF00205638.